INT66305

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1996
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 9
Total Number 10
Disease Relevance 1.70
Pain Relevance 5.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (HTR1B) cytoplasm (HTR1B) signal transducer activity (HTR1B)
Anatomy Link Frequency
dorsal 1
cranial 1
platelet 1
ear 1
raphe nucleus 1
HTR1B (Homo sapiens)
Pain Link Frequency Relevance Heat
Raphe 9 100.00 Very High Very High Very High
fluoxetine 18 99.98 Very High Very High Very High
agonist 9 99.48 Very High Very High Very High
Serotonin 27 99.32 Very High Very High Very High
substance P 6 99.26 Very High Very High Very High
Migraine 2 98.32 Very High Very High Very High
headache 1 97.56 Very High Very High Very High
Desipramine 2 91.04 High High
Hippocampus 1 90.52 High High
Sumatriptan 3 90.32 High High
Disease Link Frequency Relevance Heat
Headache 3 98.32 Very High Very High Very High
Hypotension 6 98.16 Very High Very High Very High
Syndrome 1 97.04 Very High Very High Very High
Stress 1 83.64 Quite High
Drug Dependence 3 75.00 Quite High
Pressure And Volume Under Development 2 70.84 Quite High
Depression 7 69.48 Quite High
Congenital Anomalies 1 65.08 Quite High
Pressure Volume 2 Under Development 2 64.12 Quite High
Anxiety Disorder 7 59.08 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This reduction in 5-HT1B mRNA was specific to dorsal raphe nucleus and was not found in several postsynaptic (nonserotonergic) regions.
Negative_regulation (reduction) of 5-HT1B in raphe nucleus associated with raphe
1) Confidence 0.57 Published 1996 Journal Neuropsychopharmacology Section Abstract Doc Link 8914125 Disease Relevance 0.13 Pain Relevance 1.13
However, fluoxetine reduced dorsal raphe 5-HT1B mRNA levels in a time-dependent and washout-reversible manner.
Negative_regulation (reduced) of 5-HT1B in dorsal associated with raphe and fluoxetine
2) Confidence 0.57 Published 1996 Journal Neuropsychopharmacology Section Abstract Doc Link 8914125 Disease Relevance 0.14 Pain Relevance 1.15
Interestingly, non-deprived animals receiving chronic injections showed a decrease in hippocampal 5-HT1B receptor mRNA.
Negative_regulation (decrease) of 5-HT1B
3) Confidence 0.57 Published 2002 Journal Psychoneuroendocrinology Section Abstract Doc Link 11750782 Disease Relevance 0.40 Pain Relevance 0.37
These results suggest that chronic fluoxetine may increase serotonin release from axonal terminals by down-regulating the messenger RNA coding for presynaptic 5-HT1B autoreceptors while causing only transient effects on serotonin transporter mRNA.
Negative_regulation (down-regulating) of 5-HT1B associated with serotonin and fluoxetine
4) Confidence 0.41 Published 1996 Journal Neuropsychopharmacology Section Abstract Doc Link 8914125 Disease Relevance 0.11 Pain Relevance 1.07
We conclude that hypotensive and vasorelaxant effects of eugenosedin-B can be attributed to its multiple actions on the blockade of 5-HT1B, 5-HT2A, alpha1/2 and beta1 receptors, and its ability to reduce platelet aggregation attributed to its blockade of alpha2 and 5-HT2A receptors.
Negative_regulation (blockade) of 5-HT1B in platelet associated with hypotension
5) Confidence 0.41 Published 2008 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 18287883 Disease Relevance 0.28 Pain Relevance 0.18
This suggests that 5-HT1D-receptors can regulate the release of CGRP and substance P and may be relevant to the clinical effectiveness of 5-HT1B/1D-receptor agonists in the treatment of migraine and other cranial pain syndromes.
Negative_regulation (effectiveness) of 5-HT1B in cranial associated with syndrome, migraine, agonist, headache and substance p
6) Confidence 0.41 Published 2002 Journal Cephalalgia Section Abstract Doc Link 12133041 Disease Relevance 0.29 Pain Relevance 0.57
CONCLUSIONS: Based upon these findings, no evidence was found for a specific role of the 5-HT1B/1D receptor in OCD.
Negative_regulation (role) of 5-HT1B
7) Confidence 0.41 Published 2000 Journal Psychopharmacology (Berl.) Section Body Doc Link 11041318 Disease Relevance 0 Pain Relevance 0
Reverse transcription-polymerase chain reactions revealed that HCAECs possessed only 5-HT1B and 5-HT2B receptor mRNAs. 5-HT (0.001-10 mumol/L) induced nitrite production from HCAEC.
Negative_regulation (possessed) of 5-HT1B
8) Confidence 0.41 Published 1998 Journal Kobe J Med Sci Section Abstract Doc Link 10036860 Disease Relevance 0 Pain Relevance 0.32
At day 4, this 5-HT2B-mediated inhibition of the 5-HT1B/1D function can be blocked upon concomitant 5-HT2A activation although a 5-HT2A/PLA2 positive coupling was evidenced.
Negative_regulation (inhibition) of 5-HT1B
9) Confidence 0.41 Published 1998 Journal J. Biol. Chem. Section Abstract Doc Link 9651340 Disease Relevance 0 Pain Relevance 0.07
In isolated rabbit ear artery sensitized with 16 mM K, eugenosedin-B antagonized 5-nonyloxytryptamine- and 5-HT-induced vasocontractions, indicating it also blocked 5-HT1B and 5-HT2A receptors.
Negative_regulation (blocked) of 5-HT1B in ear
10) Confidence 0.41 Published 2008 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 18287883 Disease Relevance 0.35 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox